478 related articles for article (PubMed ID: 30144541)
1. APOE ε4 is associated with higher levels of CSF SNAP-25 in prodromal Alzheimer's disease.
Wang S; Zhang J; Pan T;
Neurosci Lett; 2018 Oct; 685():109-113. PubMed ID: 30144541
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
3. APOE ε4 carriers may undergo synaptic damage conferring risk of Alzheimer's disease.
Sun X; Dong C; Levin B; Crocco E; Loewenstein D; Zetterberg H; Blennow K; Wright CB;
Alzheimers Dement; 2016 Nov; 12(11):1159-1166. PubMed ID: 27321472
[TBL] [Abstract][Full Text] [Related]
4. Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer's disease.
Giannisis A; Al-Grety A; Carlsson H; Patra K; Twohig D; Sando SB; Lauridsen C; Berge G; Grøntvedt GR; Bråthen G; White LR; Kultima K; Nielsen HM
Alzheimers Res Ther; 2022 Aug; 14(1):115. PubMed ID: 36002891
[TBL] [Abstract][Full Text] [Related]
5. Sex differences in CSF biomarkers vary by Alzheimer disease stage and
Babapour Mofrad R; Tijms BM; Scheltens P; Barkhof F; van der Flier WM; Sikkes SAM; Teunissen CE
Neurology; 2020 Oct; 95(17):e2378-e2388. PubMed ID: 32788242
[TBL] [Abstract][Full Text] [Related]
6. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
[TBL] [Abstract][Full Text] [Related]
7. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
[TBL] [Abstract][Full Text] [Related]
8. Cognitively normal APOE ε4 carriers have specific elevation of CSF SNAP-25.
Butt OH; Long JM; Henson RL; Herries E; Sutphen CL; Fagan AM; Cruchaga C; Ladenson JH; Holtzman DM; Morris JC; Ances BM; Schindler SE;
Neurobiol Aging; 2021 Jun; 102():64-72. PubMed ID: 33765432
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
[TBL] [Abstract][Full Text] [Related]
10. Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations.
Lautner R; Insel PS; Skillbäck T; Olsson B; Landén M; Frisoni GB; Herukka SK; Hampel H; Wallin A; Minthon L; Hansson O; Blennow K; Mattsson N; Zetterberg H
Alzheimers Res Ther; 2017 Oct; 9(1):87. PubMed ID: 29061195
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid levels of YKL-40 in prodromal Alzheimer's disease.
Wang L; Gao T; Cai T; Li K; Zheng P; Liu J;
Neurosci Lett; 2020 Jan; 715():134658. PubMed ID: 31794792
[TBL] [Abstract][Full Text] [Related]
12. Factors that influence the levels of cerebrospinal fluid biomarkers in memory clinic patients.
Knapskog AB; Eldholm RS; Braekhus A; Engedal K; Saltvedt I
BMC Geriatr; 2017 Sep; 17(1):210. PubMed ID: 28893185
[TBL] [Abstract][Full Text] [Related]
13. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype.
Blom ES; Giedraitis V; Zetterberg H; Fukumoto H; Blennow K; Hyman BT; Irizarry MC; Wahlund LO; Lannfelt L; Ingelsson M
Dement Geriatr Cogn Disord; 2009; 27(5):458-64. PubMed ID: 19420940
[TBL] [Abstract][Full Text] [Related]
14. The Role of Apolipoprotein E ε4 in Early and Late Mild Cognitive Impairment.
Luo Y; Tan L; Therriault J; Zhang H; Gao Y;
Eur Neurol; 2021; 84(6):472-480. PubMed ID: 34340229
[TBL] [Abstract][Full Text] [Related]
15. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
[TBL] [Abstract][Full Text] [Related]
16. CSF Aβ
Lim YY; Yassi N; Bransby L; Ayton S; Buckley RF; Eratne D; Velakoulis D; Li QX; Fowler C; Masters CL; Maruff P
Neurobiol Aging; 2023 Sep; 129():209-218. PubMed ID: 37399739
[TBL] [Abstract][Full Text] [Related]
17. Association of APOE gene with longitudinal changes of CSF amyloid beta and tau levels in Alzheimer's disease: racial differences.
Xu C; Xiao D; Su BB; Saveron JM; Gamez D; Navia RO; Wang N; Roy U; Adjeroh DA; Wang K;
Neurol Sci; 2024 Mar; 45(3):1041-1050. PubMed ID: 37759100
[TBL] [Abstract][Full Text] [Related]
18. APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study.
Cysique LA; Hewitt T; Croitoru-Lamoury J; Taddei K; Martins RN; Chew CS; Davies NN; Price P; Brew BJ
BMC Neurol; 2015 Apr; 15():51. PubMed ID: 25880550
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
[TBL] [Abstract][Full Text] [Related]
20. Plasma apolipoprotein E levels, isoform composition, and dimer profile in relation to plasma lipids in racially diverse patients with Alzheimer's disease and mild cognitive impairment.
Giannisis A; Al-Grety A; Carlsson H; Howell JC; Hu WT; Kultima K; Nielsen HM
Alzheimers Res Ther; 2023 Jul; 15(1):119. PubMed ID: 37400888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
